Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

CRC × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 512 Neoplasms 485 Carcinoma, Non-Small-Cell Lung 406 Prostatic Neoplasms 306 Lung Neoplasms 261 Colorectal Neoplasms 246 Neoplasm Metastasis 221 Multiple Myeloma 200 Leukemia, Myeloid, Acute 185 Ovarian Neoplasms 179 Pancreatic Neoplasms 154 Melanoma 148 Recurrence 140 Squamous Cell Carcinoma of Head and Neck 135 Carcinoma, Hepatocellular 133 Brain Neoplasms 124 Carcinoma, Renal Cell 120 Stomach Neoplasms 117 Urinary Bladder Neoplasms 115 Glioblastoma 110 Endometrial Neoplasms 104 Lymphoma, Non-Hodgkin 103 Triple Negative Breast Neoplasms 101 Head and Neck Neoplasms 101 Leukemia, Lymphocytic, Chronic, B-Cell 100 Precursor Cell Lymphoblastic Leukemia-Lymphoma 99 Lymphoma 97 Hematologic Neoplasms 95 Lymphoma, Large B-Cell, Diffuse 93 Glioma 91

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡